Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Causeway Therapeutics

Request full access

MicroRNA therapies for repairing chronic tendon injuries

Glasgow, United KingdomFounded 2015Biotech & Life Sciences

About Causeway Therapeutics

Causeway Therapeutics is a clinical-stage biotechnology company spun out from the University of Glasgow in 2015. The company was co-founded by Dr. Derek Gilchrist, Mr. Neal Millar, and Professor Iain McInnes. The founders' journey began in a University of Glasgow laboratory where Dr. Gilchrist and Mr. Millar discovered that a specific microRNA, miR-29a, is a critical regulator of collagen production, the proteins that provide strength to tendons. They found that a loss of this molecule is a key factor in the development of tendinopathy, a condition of chronic tendon injury.

The company's core focus is on developing microRNA-based therapies to treat musculoskeletal diseases, particularly tendinopathies, which affect one in ten people and currently have no approved specific therapies. Causeway's lead product is TenoMiR®, a synthetic mimic of miR-29a designed to be injected directly into the damaged tendon. This treatment aims to restore the natural cellular processes, repair tendon structure, reduce pain, and restore function. The company is conducting international Phase 2 clinical trials for TenoMiR® for lateral epicondylitis (tennis elbow). Beyond human health, the company is also developing an analogous therapy, EquiMiR™, for tendinopathy in horses.

Causeway Therapeutics operates on a biopharmaceutical business model, focusing on the research and development of its proprietary therapies with the goal of bringing them to market. Its revenue generation will depend on the successful commercialization of its products following clinical trials and regulatory approval. The company has successfully raised significant capital to fund its clinical trials, including a £1M seed round in 2017 and an £8.75M investment in 2023 to advance its Phase 2 trial. Key investors include Mediqventures, Scottish Enterprise, and the University of Glasgow.

Source: Dealroom company data

At a glance

Status
Operational
Employees
10
Open positions
None listed
Dealroom signal
71.0/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Drug Development, Spinout, Orthopedic, Sustainable Development Goals, Biotech and Pharma, Silver Economy, Techbio, elderly care, DT and LS
Business model
Manufacturing

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jun 2025 $3M $58M Undisclosed ↗
EARLY VC✓Equity / VC Feb 2023 $12M $46M Declan Doogan · Glasgow University Holdings · Scottish Enterprise Growth Investments · Mediqventures ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Causeway Therapeutics website traffic

Latest recorded traffic for Causeway Therapeutics is 770 monthly website visits, down 35.8% over the last three months. Causeway Therapeutics's team declined 9.1% over the past year.

Latest monthly visits770 3-month web change-35.8% 1-year team growth-9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Causeway Therapeutics in the Glasgow ecosystem

Live from Dealroom

The Causeway Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Mediqventures
  • Mediqventure
  • Scottish Enterprise Growth Investments

Series A2 investors entered at this stage

  • Declan Doogan
  • Glasgow University Holdings

Other known investors1 additional known investor

  • University of Glasgow
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Causeway Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.